News

The Manila Times on MSN14h
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclei…
Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at ...
Clinical Trials Arena on MSN11h
FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS
The US Food and Drug Administration (FDA) has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ...